2-[4-[2-[3-(3,4-Dimethoxyphenyl)-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]-1,3-thiazol-4-yl]phenyl]isoindole-1,3-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[4-[2-[3-(3,4-Dimethoxyphenyl)-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]-1,3-thiazol-4-yl]phenyl]isoindole-1,3-dione
• 化学式: C₃₂H₂₄N₄O₄S₂
• 分子量: 592.7
• InChiKey: UOEGYWWWSHVNGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  141
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• Transcription factor modulating compounds and methods of use thereof
  申请人：Levy Stuart B.

  公开号：US20090131401A1

  公开（公告）日：2009-05-21

  Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.

  本发明提供了可用作抗感染剂的取代苯并咪唑化合物，其可降低微生物的耐药性、毒力或生长。本发明还提供了制备和使用取代苯并咪唑化合物的方法，以及其制备的药物制剂，例如用于减少抗生素耐药性和抑制生物膜的制剂。
• Compounds
  申请人：CTxT Pty Limited

  公开号：US20200039945A1

  公开（公告）日：2020-02-06

  A compound of formula (I), or a pharmaceutical salt thereof:
• Benzisoxazole Sulfonamide Derivatives
  申请人：Pfizer Inc.

  公开号：US20200399258A1

  公开（公告）日：2020-12-24

  The present invention relates to compounds of formula (1) or pharmaceutically acceptable salts thereof, wherein Ring A, R 1 -R 8 , and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.
• METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
  申请人：Design Therapeutics, Inc.

  公开号：US20210238226A1

  公开（公告）日：2021-08-05

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, atxn1, atxn2, atxn3, cacna1a, atxn7, ppp2r2br tbp, htt, jph3r ar, or atn1 and treating diseases and conditions in which dmpk, atxn1, atxn2, atxn3, cacna1a, atxn1, ppp2r2b, tbp, htt, jph3, ar, or atn1 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
• Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family
  申请人：CTxT Pty Limited

  公开号：US20210380548A1

  公开（公告）日：2021-12-09

  A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1, and MOF.